SAB Biotherapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
SABS$3.07-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(12,361,200) | $(14,234,706) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,996,610 | 1,767,226 |
| Amortization of finance right-of-use assets | 43,412 | 48,209 |
| Stock-based compensation expense | 1,218,878 | 1,247,595 |
| Changes in fair value of warrant liabilities | (7,685,192) | 274,930 |
| Accretion of discounts on short-term investments | (169,393) | — |
| Professional fees settled with equity instruments | — | 143,530 |
| Changes in operating assets and liabilities | ||
| Accrued interest receivable | (224,924) | — |
| Accounts receivable | — | 5,194,842 |
| Prepaid expenses and other current assets | 398,389 | 657,689 |
| Operating lease right-of-use assets and liabilities, net | (28,462) | 266,755 |
| Accounts payable | 198,320 | (2,275,271) |
| Deferred grant income | (1,207,712) | 2,894,781 |
| Accrued expense and other current liabilities | (1,646,516) | (2,490,453) |
| Net cash used in operating activities | (18,467,790) | (6,504,873) |
| Cash flows from investing activities: | ||
| Purchases of equipment | (181,585) | (43,984) |
| Purchases of investment securities | (31,335,142) | — |
| Sales and maturities of investments | 11,376,337 | — |
| Net cash used in investing activities | (20,140,390) | (43,984) |
| Cash flows from financing activities: | ||
| Payment of deferred issuance costs | (236,105) | — |
| Payments of notes payable | (435,031) | (660,772) |
| Principal payments on finance leases | (64,733) | (64,696) |
| Proceeds from exercise of stock options | 20,412 | 1,890 |
| Net cash used in financing activities | (715,457) | (723,578) |
| Effect of exchange rate changes on cash and cash equivalents | 13 | — |
| Net decrease in cash and cash equivalents | (39,323,624) | (7,272,435) |
| Cash and cash equivalents | ||
| Beginning of period | 56,566,066 | 15,046,894 |
| End of period | $17,242,442 | $7,774,459 |
| Supplemental cash flow information: | ||
| Cash paid for interest | $149,102 | $120,022 |
| Supplemental information on non-cash investing and finance activities: | ||
| Settlement of accrued liabilities through the issuance of common stock | $— | $1,500,000 |
| Right-of-use assets obtained in exchange for operating lease liabilities | $368,425 | $— |
See accompanying notes to the condensed consolidated financial statements.
SAb Biotherapeutics, Inc. and subsidiaries
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.